Navigation Links
PDL BioPharma Announces Third Quarter 2011 Financial Results
Date:11/9/2011

INCLINE VILLAGE, Nev., Nov. 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

RevenuesTotal revenues for the third quarter of 2011 were $83.8 million, compared to $86.4 million for the same period of 2010, a three percent year-over-year decrease. Total revenues for the nine months ended September 30, 2011, were $289.2 million, compared to $268.8 million for the same period of 2010, an eight percent increase.

The third quarter 2011 revenue decline is driven primarily by reduced royalties from second quarter 2011 sales of Avastin® partially offset by increased royalties from second quarter 2011 sales of Herceptin®, Lucentis® and Tysabri®. Also contributing to the decline is a lower average royalty rate on sales of Avastin, Herceptin, Lucentis and Xolair® (the Genentech Products) that are either made or sold in the United States (U.S.-based Sales) due to higher year-to-date sales in 2011. Sales of the Genentech Products are subject to a tiered royalty rate for U.S.-based Sales and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States. Due to the tiering, in the second quarter of 2011, only 15% of U.S.-based Sales were above the lowest royalty rate of one percent as compared with 45% of U.S.-based Sales for the second quarter 2010. The net sales thresholds and the applicable royalty rates for product that is either made or sold in the United States are outlined below:   Royalty RateNet sales up to $1.5 billion

3.0%Net sales between $1.5 billion and $2.5 billion

2.5%Net sales between $2.5 billion and $4.0 billion

2.0%Net sales e
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
3. PDL BioPharma to Announce Third Quarter 2011 Financial Results on November 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
5. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
6. Sentry BioPharma Services Earns a GSA Federal Supply Schedule Contract #GS-10F-0432X
7. Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
8. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
9. CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan
10. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
11. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
(Date:4/25/2015)... 25, 2015 The Hon. Ellen Tauscher, ... issues the following statement following the deadly earthquake in ... Nepal, resulting in the deaths of more than 1,000 ... felt across Nepal, Bangladesh, India and other parts of ... condolences to the people of Nepal and the families ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 By definition, a ... data for the enterprise relying on their judgement and expertise ... But according to an article published in National ... times actually be doing a disservice to their responsibilities by ... dotted and t’s are crossed when it comes to company ...
(Date:4/25/2015)... 25, 2015 Parker and Sons projects growth ... has spiked in Arizona alongside the growing economy. As a ... employees for April to help account for the rising need ... in April is something we are enthusiastic about. It means ... Kelly, president at Parker and Sons. , Indeed, Parker and ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI Day has been ... nation! This year, on May 5th, 2015, Secura Consultants is ... Day on the road by supporting the first ever National ... CLTC, Chief Executive Officer at Secura Consultants and co-creator of ... stating, "The first Twin Cities DI Day was a hugely ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 As the ... and the unique sacrifices of these young men and ... Service members, Veterans and their Families” presents a special ... is designed to gain a better understanding of the ... and wellness. For those – civilian and military – ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2
... ... MRSA. Jan-Pro, Global Leader in Commercial Cleaning, Once Again Leads the Way in Infection ... Solution in the control of infectious microorganisms - EnviroShield Disinfectant Technology , ... (PRWEB) June 1, 2010 -- ...
... , ... of Midbrook, Inc.) is proud to announce they have recently been awarded an agreement with ... the nation’s largest healthcare group purchasing organizations and serves 2,300 hospitals and more than 66,000 ... ...
... GIA announces the ... Proteins market is anticipated to reach 472.3 million pounds by 2015, driven largely by functional ... processing and investments in R&D are other major driving forces for the growth of the ... San ...
... ... purchase used equipment from CosmeticLaserWorld.com can now rely on a brand new buy back ... (PRWEB) ... and doctors, recently unveiled yet another reason savvy spas should purchase equipment from the ...
... resulting from an inherited defect that prevents the proper metabolism ... milk. Exposure of affected people to galactose, can damage most ... to study the disease is limited by a lack of ... and flies may provide scientists with useful clues. The ...
... The American College of Radiology,s (ACR) Task Force on ... Organizations has proposed several steps that can help improve ... they service, according to an article in the June ... of Radiology ( www.jacr.org ). "The ...
Cached Medicine News:Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 2Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 3Health News:Midbrook Medical Announces Agreement with Premier Partners L.P. 2Health News:Midbrook Medical Announces Agreement with Premier Partners L.P. 3Health News:US Whey Proteins Market to Reach 472.3 Million Pounds by 2015, According to New Report by Global Industry Analysts, Inc. 2Health News:US Whey Proteins Market to Reach 472.3 Million Pounds by 2015, According to New Report by Global Industry Analysts, Inc. 3Health News:CosmeticLaserWorld.com Gives Buyers Peace of Mind Through Industry-Leading Investment Protection Plan 2Health News:Flies offer insight into human metabolic disease 2Health News:ACR task force makes recommendations for improving relationships between radiologists and hospitals 2
... is the only control for ... patient synovial fluid samples performed ... is also an aid for ... indicate a pathological condition present ...
... control with stabilized human blood cells provides ... the processing and centrifugation of urine prior ... regulations. Microscopic evaluation of urine sediment is ... use of controls. Qualitative and quantitative values ...
... a two-level control compatible with popular ... Strips and Roche Micral test strips. ... turbidimetric immunoassays using AU Series, Bayer ... Cobas, Diasorin SPQ Test System, Dimension, ...
... This control is designed to validate visual and ... dipstick into the control the same way ... is the addition of creatinine and microalbumin. Values ... for hCG for early pregnancy detection test methods. ...
Medicine Products: